Introduction
============

Esophageal cancer (EC) has been ranked as the eighth most common cancer and the sixth leading cause of cancer-related deaths worldwide.[@b1-cmar-10-5395] Its epidemiology varies widely, particularly in incidence rates among geographic regions.[@b2-cmar-10-5395] The latest epidemiological studies indicated the highest rate of EC located on the "esophageal cancer belt" ie, China, South Africa, and France.[@b3-cmar-10-5395],[@b4-cmar-10-5395] Possible risk factors for EC include alcohol drinking, hot-temperature food items, cigarette smoking, chronic mucosal irritation, and a family history of cancers.[@b5-cmar-10-5395]--[@b7-cmar-10-5395] Deficiency of nutrients, such as vitamins and micro-elements, was also found to be associated with an increased risk of EC, whereas a high intake of fruit and vegetables has been considered to be effective in prevention.[@b6-cmar-10-5395] Several previous research studies have evaluated the effect of beta-carotene, vitamin A, C, and E on EC.[@b8-cmar-10-5395]--[@b17-cmar-10-5395] Regarding multivitamin B, most studies only examined folate intake and EC risk, and no relevant pooled analyses have been performed. Thus, we conducted a meta-analysis of the current epidemiological articles to better characterize the association between multivitamin B intake and EC risk.

Materials and methods
=====================

Search strategy
---------------

We conducted a systematic search for published articles and abstracts that evaluated the relationships between B vitamins (B1, B2, B3, B5, B6, B9, B12) and the risk of esophageal carcinoma in humans.

We conducted systemic searches of PubMed (Medline), ScienceDirect, and Cochrane Library electronic databases (from database inception to December 2017). The searches were performed using ((((cohort studies) OR case--control studies)) AND (((((((((((((vitamin B) OR vitamin B1) OR vitamin B2) OR vitamin B3) OR vitamin B5) OR vitamin B6) OR vitamin B9) OR vitamin B12) OR thiamin) OR riboflavin) OR pyridoxal) OR folate) OR cyanocobalamin)) AND (((((cancer) OR neoplasm) OR carcinoma)) AND Esophag\*) in all fields. In addition, we scrutinized references from relevant original reports, review articles, and meta-analyses to identify other appropriate studies.

Inclusion criteria
------------------

In order to be included, the following criteria were needed: 1) the study was designed as a cohort, nested case--control or case--control study; 2) the study reported vitamin B and any kind of B vitamin group intake and the risk of EC; 3) the results reported effect estimates (RR, OR) and 95% CIs for comparisons between high and low dietary vitamin B intake. When multiple levels of vitamin B intake were presented, the ratio comparing the highest intake vs the lowest intake was chosen. When data from several publications were overlapping, we selected the articles with the most comprehensive data for inclusion in this meta-analysis.

Data extraction and quality assessment
--------------------------------------

Two researchers independently reviewed titles and abstracts of potentially eligible research identified by the search strategy and extracted the date using a standard extraction form from each included publication: the first author's name, publication year, source of control, study design, country where the study was performed, type of cancer, specific vitamin measured, number of cases, number of controls or cohort size, total sample size, lowest vitamin B level, highest vitamin B level, difference between the highest and lowest vitamin B levels, and the risk estimates on EC and corresponding 95% CIs for the highest vs lowest categories of vitamin B intake or for each category, factors adjusted for. Adjusted ratios were extracted in preference to non-adjusted ratios.

Two authors independently assessed the quality of included studies using the Newcastle--Ottawa Scale (NOS), which is a validated scale for assessing the quality of non-randomized studies in meta-analyses.[@b18-cmar-10-5395],[@b19-cmar-10-5395] This scale awards a maximum of 9 points to each study: 4 for selection of participants and measurement of exposure, 2 for comparability of cohorts on the basis of the design or analysis, and 3 for evaluation of methodological quality outcomes. We assigned scores of 7 or higher to high-quality studies.[@b20-cmar-10-5395],[@b21-cmar-10-5395]

Statistical analyses
--------------------

In this meta-analysis, we calculated effect estimates (RR or OR) and 95% CIs in each study to evaluate the relationship between vitamin B intake and the risk of EC. We used a fixed effects model (Mantel--Haenszel method) when heterogeneity was negligible, and a random effects model (DerSimonian and Laird method) when heterogeneity was significant. Heterogeneity was assessed using *I*^2^ statistic. Significant heterogeneity was indicated if *I*^2^ values were greater than 50%.[@b22-cmar-10-5395],[@b23-cmar-10-5395] We also performed a sensitivity analysis by removing individual studies from the meta-analysis when statistically significant heterogeneity was detected. We also used Egger's and Begg's tests to assess publication bias.[@b24-cmar-10-5395],[@b25-cmar-10-5395] All tests were two-sided and results were regarded as statistically significant if *P*\<0.05. All statistical analyses were done by using STATA software (version 12.0; StataCorp LP, College Station, TX, USA).

Results
=======

Literature search
-----------------

[Figure 1](#f1-cmar-10-5395){ref-type="fig"} shows the literature search results and screening of this study. We identified 390 observational studies from PubMed (Medline), ScienceDirect, and Cochrane Library. A total of 332 articles were assessed after eliminating 58 duplicate papers. A total of 268 articles were excluded owing to reported irrelevant results after reviewing the title and abstract. In addition, three additional studies were found by a manual search of the reference lists. In total, full text of 67 articles was reviewed. Among them, 13 studies did not show the association of vitamin B and EC risk, because these 13 articles explored the relationship between nutrient intervention or mineral compound vitamin B or all the nutrient intake and risk of EC or precancerous lesions. Four articles did not report sufficient data for estimation of OR/RR, three articles did not separately report the 95% CI, nine articles were reviews, 12 articles reported the prognosis of EC patients, five articles focused on gene type and vitamin B exposures, and two articles focused on blood vitamin B9, B12. As a result, 19 articles were finally selected for the meta-analysis.[@b8-cmar-10-5395],[@b9-cmar-10-5395],[@b26-cmar-10-5395]--[@b42-cmar-10-5395]

Characteristics and quality of included studies
-----------------------------------------------

We identified 19 articles in our study. [Tables 1](#t1-cmar-10-5395){ref-type="table"} and [2](#t2-cmar-10-5395){ref-type="table"} show the main characteristics extracted from included studies. All the studies were conducted in Asia, Europe, America, and Australia and were published from 1988 to 2017. Among all the studies, one study was a cohort study[@b42-cmar-10-5395] and 18 studies were case--control studies.[@b8-cmar-10-5395],[@b9-cmar-10-5395],[@b26-cmar-10-5395]--[@b41-cmar-10-5395]

The quality of all studies was assessed by using the NOS scale. The overall methodological quality of articles is presented in [Table 1](#t1-cmar-10-5395){ref-type="table"}. Overall, eleven studies had a score of 8,[@b26-cmar-10-5395],[@b27-cmar-10-5395],[@b30-cmar-10-5395],[@b32-cmar-10-5395],[@b33-cmar-10-5395],[@b35-cmar-10-5395]--[@b40-cmar-10-5395] four had a score of 7,[@b8-cmar-10-5395],[@b9-cmar-10-5395],[@b34-cmar-10-5395],[@b42-cmar-10-5395] and the remaining studies had a score of 6.[@b28-cmar-10-5395],[@b29-cmar-10-5395],[@b36-cmar-10-5395],[@b37-cmar-10-5395],[@b39-cmar-10-5395],[@b41-cmar-10-5395]

Multivitamin B intake
---------------------

Our results showed a statistically significant inverse association between use of multivitamin B supplements and EC (OR=0.70; 95% CI: 0.59--0.83). There was statistically significant heterogeneity among all the studies (*I*^2^=77.9%; *P*=0.00).

Subgroup analysis of the source of the control group
----------------------------------------------------

Subgroup analysis of the source of the control group showed that dietary vitamin B was a protective factor for EC in both subgroups (hospital-based: OR=0.575, 95% CI: 0.492--0.672; population-based: OR=0.868, 95% CI: 0.820--0.919).

Subgroup analysis of EC pathological types
------------------------------------------

Subgroup analysis based on EC pathological types showed that dietary vitamin B was protective against esophageal squamous cell carcinoma (OR=0.762, 95% CI: 0.697--0.833) and esophageal adenocarcinoma (OR=0.870, 95% CI: 0.811--0.933).

Vitamin B1 intake
-----------------

The association between vitamin B1 intake and EC risk was examined in seven case--control studies. The multivariable adjusted ORs for each study and combination of all studies for the highest vs lowest level of dietary vitamin B1 intake are shown in [Figure 2](#f2-cmar-10-5395){ref-type="fig"}. The pooled OR of EC for the highest vs lowest level of vitamin B1 intake was 0.68 (95% CI: 0.56--0.82). No heterogeneity was detected (*I*^2^=0.0%, *P*=0.432). It was not possible to perform dose--response meta-analyses due to limited data.

Vitamin B2 intake
-----------------

We did not observe a statistically significant association for vitamin B2 supplements and EC risk ([Figure 3](#f3-cmar-10-5395){ref-type="fig"}, OR=0.86; 95% CI: 0.64--1.16) based on eleven studies. There was statistically significant heterogeneity among the studies on dietary vitamin B2 intake (*I*^2^=70.2%; *P*\<0.001).

Vitamin B3 intake
-----------------

As shown in [Figure 4](#f4-cmar-10-5395){ref-type="fig"}, seven studies examined the association between vitamin B3 intake and EC risk. The pooled OR for the highest vs lowest vitamin B3 intake was 0.70 (95% CI: 0.53--0.94, *I*^2^=53.9%, *P*=0.043). Dose--response meta-analyses were not done due to data limitations.

Vitamin B5 intake
-----------------

There was only one study which showed the association between vitamin B5 intake and EC risk (OR=0.49, 95% CI:0.20--1.20), suggesting that vitamin B5 intake was not significantly associated with the risk of EC.

Vitamin B6 intake
-----------------

A total of 13 studies assessed the association between dietary vitamin B6 intake and EC risk. [Figure 5](#f5-cmar-10-5395){ref-type="fig"} shows that the pooled OR of EC risk for the highest vs the lowest categories of vitamin B6 intake was 0.64 (95% CI: 0.49--0.83, *I*^2^=73.0%, *P*=0.00), indicating that vitamin B6 intake had a protective effect against EC risk. For an increase of 100 µg/day of dietary vitamin B6 intake, a statistically significant, inverse association with EC risk (OR=0.98, 95% CI: 0.98--0.99) was detected.

Vitamin B9 intake
-----------------

The association between dietary folate intake and EC risk was examined in 15 studies. The multivariable adjusted ORs for each study and combination of all studies for the highest vs lowest level of dietary folate intake are shown in [Figure 6](#f6-cmar-10-5395){ref-type="fig"}. The pooled OR of EC for the highest vs lowest level of dietary folate intake was 0.63 (95% CI: 0.56--0.71). There was statistically significant heterogeneity among the studies on dietary folate intake (*I*^2^=70.2%; *P*=0.00). Dose--response meta-analysis was based on seven studies. A statistically significant, inverse association was observed for an increase of 100 µg/day in supplemental vitamin B9 and EC risk (OR=0.89; 95% CI: 0.86--0.94).

Vitamin B12 intake
------------------

Inconsistent associations were observed for use of vitamin B12 supplements and EC risk in our study (OR=1.34, 95% CI: 1.05--1.70). Heterogeneity was high (*I*^2^=73.6%, *P*=0.00), as shown in [Figure 7](#f7-cmar-10-5395){ref-type="fig"}. Using restricted cubic spline function, we found a potential non-linear dose--response association between dietary vitamin B12 intake and EC risk (*P*~non-linearity~=0.0001) ([Figure 8](#f8-cmar-10-5395){ref-type="fig"}). The non-linear curve showed that there was a dose--response association between vitamin B12 dose and decreased risk of EC approximately below 5.5 µg/day, whereas the EC risk did not decrease further above 5.5 µg/day.

Publication bias
----------------

Publication bias was evaluated by Egger's[@b24-cmar-10-5395] and Begg's tests.[@b25-cmar-10-5395] The results disclosed no evidence of publication bias for EC (Egger: *t*=0.38, *P*=0.575; Begg: *z*=1.34 *P*=0.179).

Sensitivity analysis
--------------------

As a result, a sensitivity analysis of multivitamin B intake was conducted, and after each study was sequentially excluded from the pooled analysis, the conclusion was not affected by exclusion of any specific study.

Discussion
==========

Epidemiological investigations have suggested that there are significant relationships between diet-associated factors and EC. B vitamins may be one factor. Because some B vitamins cannot be synthesized in the human body, they can only be obtained through dietary. Fruit and vegetables are important dietary sources of some B vitamins. The reason why vitamin B affects the risk of cancer may be because it is essential for the biosynthesis of nucleotides, replication of DNA, supply of methyl groups, and the growth and repair of cells.[@b43-cmar-10-5395]--[@b46-cmar-10-5395]

In the present review, there was no epidemiologic research that assessed the association between total B vitamin consumption and EC risk among people. There were only studies which evaluated the relationship between several subclasses of B vitamins and EC risk. Thus, this study is the most comprehensive meta-analysis providing evidence to indicate these results. We found that total vitamin B intake was significantly associated with reduced EC risk. In addition, we evaluated the potential association of vitamin B subclasses and EC risk, respectively. In the subgroup analysis, we found that vitamin B1, B3, B6, and B9 may be protective factors, but vitamin B12, in contrast, was positively associated with risk of EC.

Previous studies have shown that consuming large quantities of vegetables, fruit, vitamins, and antioxidants can reduce the risk of EC.[@b47-cmar-10-5395]--[@b49-cmar-10-5395] One potential reason for vitamin B12 being different from other B vitamins may be because it is derived exclusively from foods of animal origin, and it is simply a marker for consumption of animal protein. In previous studies, the risk of adenocarcinomas of the esophagus was linked to high-fat diets[@b50-cmar-10-5395],[@b51-cmar-10-5395] because esophageal adenocarcinoma generally arises from Barrett's epithelium.[@b52-cmar-10-5395] Additionally, research has shown that diets low in animal protein and rich in fruit, vegetables, and fiber can reduce the risk of malignant transformation.[@b33-cmar-10-5395],[@b47-cmar-10-5395]

B-group vitamin supplementation may have antioxidant and anti-inflammatory effects.[@b53-cmar-10-5395],[@b54-cmar-10-5395] The biological mechanisms responsible for the protective effect of high-dosage vitamin B are unclear. One possible explanation is that B vitamins and additional nutrients sourced from fruit and vegetables are involved in the one-carbon metabolism.[@b55-cmar-10-5395]--[@b57-cmar-10-5395] The metabolic pathway of one-carbon metabolism has been frequently implicated in carcinogenesis, because of its involvement in maintaining nucleotide biosynthesis and methylation reactions. Imbalances and deficiencies among crucial one-carbon metabolism nutrients may interfere with DNA replication, DNA repair, and regulation of gene expression, any of which could promote carcinogenesis.[@b58-cmar-10-5395],[@b59-cmar-10-5395] Like the vitamin B3, vitamin B6 and vitamin B9, they are indispensable in the biosynthesis of four bases of DNA (thymidine, guanine, adenine, and cytosine). Deficiency of one or more of the three vitamins required for DNA maintenance is known to cause abnormal pairing of the four bases, which can then result in mutations and the development of cancer.[@b60-cmar-10-5395] Intake of vitamin B6 was reported to increase immunoglobulin G and T4(helper) lymphocytes in humans.[@b61-cmar-10-5395] Folate deficiency was suggested to be related to increased carcinogenesis, an effect that may be mediated through participation in methyl metabolism.[@b62-cmar-10-5395]

Limitations
===========

There were some limitations in our study that should be addressed. First, most studies included in our analysis were case--control studies, which may have caused recall bias, and could have caused potential heterogeneity, although the methodological quality of these observational studies was medium to high. More prospective cohort studies are needed to test this association. Second, it was a challenge to evaluate the quantity of vitamin B intake accurately because vitamin B can be sourced from various food types, and may be influenced by the type of cultivation, crop variety and location, as well as the specific morphological part of the plant eaten.

In conclusion, results from the present meta-analysis indicate that vitamin B intake is inversely associated with EC risk.

Conclusion
==========

Our findings support that vitamin B may have an influence on carcinogenesis of the esophagus. Vitamin B1, B3, B6, and B9 showed a decreased risk of EC, vitamin B12 showed an increased risk of EC. (It is clear that scientists must apply the very best science in characterizing the safety of vitamin supplements.)
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Characteristics of studies on B vitamin intake and esophageal cancer risk

  Author              Year   Source of control   Study of design        Country           Cancer type   Vitamin B   Exposure ascertainment   OR (95% CI) for highest vs lowest category   Participants (cases)   Adjust variables                                                                                                                                                                   New Castle--Ottawa scale
  ------------------- ------ ------------------- ---------------------- ----------------- ------------- ----------- ------------------------ -------------------------------------------- ---------------------- ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- --------------------------
                                                                                                                                                                                                                                                                                                                                                                                                    
  Jessri et al        2011   HB                  Case--control          Iran              ESCC          VB1         FFQ                      0.34 (0.06--2.85)                            144 (48)               Age, gender, energy intake, BMI, smoking status, physical activity, education level, gastroesophageal reflux disease symptoms                                                      8
  Ibiebele et al      2011   PB                  Case--control          Australian        EAC           VB1         FFQ                      0.78 (0.57--1.07)                            519 (147)              Age, gender, education, BMI, alcohol intake, smoking status, energy intake, NSAID use                                                                                              8
                                                                                          ESCC          VB1         FFQ                      0.41 (0.25--0.67)                            429 (57)               Age, gender, education, BMI, alcohol intake, smoking status, energy intake, NSAID use                                                                                              8
  Mayne et al         2001   PB                  Case--control          US                EAC           VB1         FFQ                      0.73 (0.50--1.07)                            969 (282)              Age, gender, site, race, proxy status, income, education, BMI, smoking status, alcohol, energy intake                                                                              8
                                                                                          ESCC          VB1         FFQ                      0.78 (0.46--1.30)                            893 (206)              Age, gender, site, race, proxy status, income, education, BMI, smoking status, alcohol, energy intake                                                                              8
  Zhang et al         1997   HB                  Case--control          US                EAC           VB1         FFQ                      0.80 (0.30--2.10)                            48 (18)                NR                                                                                                                                                                                 6
  Brown et al         1988   HB                  Case--control          US                EC            VB1         FFQ                      0.60 (0.30--1.10)                            629 (207)              Smoking status, alcohol intake                                                                                                                                                     6
  Sharp et al         2013   PB                  Case--control          Ireland           EAC           VB2         FFQ                      1.07 (0.63--1.82)                            129 (64)               Age, gender, total energy intake                                                                                                                                                   9
  Jessri et al        2011   HB                  Case--control          Iran              ESCC          VB2         FFQ                      0.22 (0.07--0.86)                            144 (48)               Age, gender, energy intake, BMI, smoking status, physical activity, education level, gastroesophageal reflux disease symptoms                                                      8
  Ibiebele et al      2011   PB                  Case--control          Australian        EAC           VB2         FFQ                      1.32 (0.98--1.80)                            518 (146)              Age, gender, education, BMI, alcohol intake, smoking status, energy intake, NSAID use                                                                                              8
                                                                                          ESCC          VB2         FFQ                      0.78 (0.50--1.21)                            422 (50)               Age, gender, education, BMI, alcohol intake, smoking status, energy intake, NSAID use                                                                                              8
  Mayne et al         2001   PB                  Case--control          US                EAC           VB2         FFQ                      1.11 (0.82--1.52)                            969 (282)              Age, gender, site, race, proxy status, income, education, BMI, smoking status, alcohol, energy intake                                                                              8
                                                                                          ESCC          VB2         FFQ                      1.26 (0.84--1.89)                            893 (206)              Age, gender, site, race, proxy status, income, education, BMI, smoking status, alcohol, energy intake                                                                              8
  Bao et al           2013   PB                  Case--control          China             ESCC          VB2         Serum                    0.46 (0.32--0.67)                            212 (106)              Age, gender, site                                                                                                                                                                  7
  Fanidi et al        2014   PB                  Nested case--control   European          ESCC          VB2         Serum                    1.21 (0.54--2.72)                            252 (123)              Age, gender, country, educational attainment, smoking status, alcohol intake                                                                                                       8
                                                                                          EAC           VB2         Serum                    1.95 (0.84--4.52)                            268 (26)               Age, gender, country, educational attainment, smoking status, alcohol intake                                                                                                       8
  Zhang et al         1997   HB                  Case--control          US                EAC           VB2         Food records             0.40 (0.20--1.10)                            44 (13)                NR                                                                                                                                                                                 6
  Chen et al          2009   PB                  Case--control          US                EAC           VB2         Validated HHHQ           0.50 (0.20--1.00)                            573 (124)              Age, gender, respondent type, BMI, alcohol intake, tobacco use, education level, family history, vitamin supplement use                                                            8
  Jessri et al        2011   HB                  Case--control          Iran              ESCC          VB3         FFQ                      0.38 (0.15--1.82)                            144 (48)               Age, gender, energy intake, BMI, smoking status, physical activity, education level, gastroesophageal reflux disease symptoms                                                      8
  Ibiebele et al      2011   PB                  Case--control          Australian        EAC           VB3         FFQ                      0.71 (0.52--0.96)                            515 (143)              Age, gender, education, BMI, alcohol intake, smoking status, energy intake, NSAID use                                                                                              8
                                                                                          ESCC          VB3         FFQ                      0.69 (0.43--1.12)                            421 (49)               Age, gender, education, BMI, alcohol intake, smoking status, energy intake, NSAID use                                                                                              8
  Mayne et al         2001   PB                  Case--control          US                EAC           VB3         FFQ                      1.07 (0.77--1.48)                            969 (282)              Age, gender, site, race, proxy status, income, education, BMI, smoking status, alcohol, energy intake                                                                              8
                                                                                          ESCC          VB3         FFQ                      0.74 (0.48--1.16)                            893 (206)              Age, gender, site, race, proxy status, income, education, BMI, smoking status, alcohol, energy intake                                                                              8
  Zhang et al         1997   HB                  Case--control          US                EAC           VB3         FFQ                      0.20 (0.10--0.70)                            44 (13)                NR                                                                                                                                                                                 6
  Chen et al          2009   PB                  Case--control          US                EAC           VB3         Validated HHHQ           0.80 (0.40--1.50)                            573 (124)              Age, gender, respondent type, BMI, alcohol intake, tobacco use, education level, family history, vitamin supplement use                                                            8
  Jessri et al        2011   HB                  Case--control          Iran              ESCC          VB5         FFQ                      0.49 (0.35--2.08)                            144 (48)               Age, gender, energy intake, BMI, smoking status, physical activity, education level, gastroesophageal reflux disease symptoms                                                      8
  Sharp et al         2013   PB                  Case--control          Ireland           EAC           VB6         FFQ                      0.37 (0.22--0.63)                            142 (46)               Age, gender, total energy intake                                                                                                                                                   9
  Jessri et al        2011   HB                  Case--control          Iran              ESCC          VB6         FFQ                      0.17 (0.05--0.91)                            145 (49)               Age, gender, energy intake, BMI, smoking status, physical activity, education level, gastroesophageal reflux disease symptoms                                                      8
  Ibiebele et al      2011   PB                  Case--control          Australian        EAC           VB6         FFQ                      0.53 (0.39--0.74)                            517 (146)              Age, gender, education, BMI, alcohol intake, smoking status, energy intake, NSAID use                                                                                              8
                                                                                          ESCC          VB6         FFQ                      0.66 (0.42--1.05)                            423 (52)               Age, gender, education, BMI, alcohol intake, smoking status, energy intake, NSAID use                                                                                              8
  Xiao et al          2014   PB                  cohort                 US                ESCC          VB6         FFQ                      0.86 (0.51--1.45)                            4,471,303 (25)         Age, gender, race, education, marital status, health status, BMI, smoking status, alcohol, vigorous physical activity, multivitamin use, family history of cancer, energy intake   7
                                                                                          EAC           VB6         FFQ                      1.00 (0.76--1.32)                            4,471,303 (98)         Age, gender, race, education, marital status, health status, BMI, smoking status, alcohol, vigorous physical activity, multivitamin use, family history of cancer, energy intake   7
  Mayne et al         2001   PB                  Case--control          US                EAC           VB6         FFQ                      0.53 (0.38--0.73)                            969 (282)              Age, gender, site, race, proxy status, income, education, BMI, smoking status, alcohol, energy intake                                                                              8
                                                                                          ESCC          VB6         FFQ                      0.45 (0.30--0.69)                            893 (206)              Age, gender, site, race, proxy status, income, education, BMI, smoking status, alcohol, energy intake                                                                              8
  Fanidi et al        2014   PB                  Nested Case--control   European          ESCC          VB6         Serum                    2.26 (1.06--4.84)                            257 (128)              Age, gender, country, educational attainment, smoking status, alcohol intake                                                                                                       8
                                                                                          EAC           VB6         Serum                    0.63 (0.30--1.33)                            270 (16)               Age, gender, country, educational attainment, smoking status, alcohol intake                                                                                                       8
  Galeone et al       2006   HB                  Case--control          Italy and Swiss   ESCC          VB6         FFQ                      0.99 (0.60--1.31)                            405 (108)              Age, center, education, BMI, smoking, alcohol drinking                                                                                                                             7
  Zhang et al         1997   HB                  Case--control          US                EAC           VB6         FFQ                      0.20 (0.10--0.70)                            44 (13)                NR                                                                                                                                                                                 6
  Chen et al          2009   PB                  Case--control          US                EAC           VB6         Validated HHHQ           0.7 (0.30--1.30)                             573 (124)              Age, gender, respondent type, BMI, alcohol intake, tobacco use, education level, family history, vitamin supplement use                                                            8
  Ling                2013   PB                  Case--control          China             ESCC          VB9         Serum                    0.11 (0.04--0.33)                            48 (6)                 Age, gender, smoking habit, drinking                                                                                                                                               8
  Sharp et al         2013   PB                  Case--control          Ireland           EAC           VB9         FFQ                      0.52 (0.30--0.89)                            136 (55)               Age, gender, total energy intake                                                                                                                                                   8
  Zhao et al          2011   HB                  Case--control          China             ESCC          VB9         FFQ                      0.61 (0.36--1.07)                            174 (52)               Age, gender                                                                                                                                                                        6
  Jessri et al        2011   HB                  Case--control          Iran              ESCC          VB9         FFQ                      0.08 (0.02--0.90)                            144 (48)               Age, gender, energy intake, BMI, smoking status, physical activity, education level, gastroesophageal reflux disease symptoms                                                      8
  Chang et al         2015   PB                  Case--control          China             EC            VB9         Plasma                   1.58 (0.95--2.64)                            178 (75)               Age, gender, BMI, education, smoking status, alcohol drinking frequency                                                                                                            8
  Ibiebele et al      2011   PB                  Case--control          Australian        EAC           VB9         FFQ                      0.72 (0.53--0.98)                            491 (117)              Age, gender, education, BMI, alcohol intake, smoking status, energy intake, NSAID use                                                                                              8
                                                                                          ESCC          VB9         FFQ                      0.78 (0.51--1.19)                            430 (56)               Age, gender, education, BMI, alcohol intake, smoking status, energy intake, NSAID use                                                                                              8
  Aune et al          2011   HB                  Case--control          Uruguay           EC            VB9         FFQ                      0.29 (0.14--0.60)                            2,102 (70)             Age, gender, residence, education, income, interviewer, smoking status, alcohol, dietary fiber, iron, BMI, energy intake                                                           7
  Xiao et al          2014   PB                  cohort                 US                ESCC          VB9         FFQ                      1.07 (0.59--1.94)                            4471303 (21)           Age, gender, race, education, marital status, health status, BMI, smoking status, alcohol, vigorous physical activity, multivitamin use, family history of cancer, energy intake   7
                                                                                          EAC           VB9         FFQ                      1.00 (0.76--1.31)                            4471303 (98)           Age, gender, race, education, marital status, health status, BMI, smoking status, alcohol, vigorous physical activity, multivitamin use, family history of cancer, energy intake   7
  Mayne et al         2001   PB                  Case--control          US                EAC           VB9         FFQ                      0.48 (0.36--0.66)                            969 (282)              Age, gender, site, race, proxy status, income, education, BMI, smoking status, alcohol, energy intake                                                                              8
                                                                                          ESCC          VB9         FFQ                      0.58 (0.39--0.86)                            893 (206)              Age, gender, site, race, proxy status, income, education, BMI, smoking status, alcohol, energy intake                                                                              8
  Bao et al           2013   PB                  Case--control          China             ESCC          VB9         Serum                    0.43 (0.29--0.62)                            212 (106)              Age, gender, site                                                                                                                                                                  7
  Fanidi et al        2014   PB                  Nested case--control   European          ESCC          VB9         Serum                    1.03 (0.47--2.24)                            255 (126)              Age, gender, country, educational attainment, smoking status, alcohol intake                                                                                                       8
                                                                                          EAC           VB9         Serum                    1.68 (0.79--3.56)                            274 (26)               Age, gender, country, educational attainment, smoking status, alcohol intake                                                                                                       8
  Galeone et al       2006   HB                  Case--control          Italy and Swiss   ESCC          VB9         FFQ                      0.68 (0.46--1.00)                            404 (90)               Age, center, education, BMI, smoking, alcohol drinking                                                                                                                             7
  Tavani et al        2012   HB                  Case--control          Italy             EC            VB9         FFQ                      0.26 (0.14--0.48)                            443 (128)              Age, gender, study center, year of interview, education, alcohol drinking, tobacco smoking, BMI, energy intake, physical activity                                                  6
  Bollschweil et al   2002   PB                  Case--control          Germany           EAC           VB9         FFQ                      5.00 (2.10--13.60)                           38 (25)                NR                                                                                                                                                                                 6
                                                                                          ESCC          VB9         FFQ                      3.20 (1.30--9.10)                            29 (16)                NR                                                                                                                                                                                 6
  Zhang et al         1997   HB                  Case--control          US                EAC           VB9         FFQ                      0.70 (0.30--1.70)                            49 (18)                NR                                                                                                                                                                                 6
  Qin et al           2008   HB and PB           Case--control          China             EC            VB9         FFQ                      0.52 (0.33--0.82)                            360 (120)              NR                                                                                                                                                                                 5
  Brown et al         1988   HB                  Case--control          US                EC            VB9         FFQ                      0.70 (0.40--1.30)                            629 (207)              Smoking status, alcohol intake                                                                                                                                                     6
  Chen et al          2009   PB                  Case--control          US                EAC           VB9         HHHQ                     0.50 (0.30--1.00)                            573 (124)              Age, gender, respondent type, BMI, alcohol intake, tobacco use, education level, family history, vitamin supplement use                                                            8
  Yang et al          2005   HB                  Case--control          Japan             EC            VB9         SQFFQ                    0.77 (0.45--1.31)                            270 (62)               Smoking status, alcohol intake, total energy intake                                                                                                                                6
  Sharp et al         2013   PB                  Case--control          Ireland           EAC           VB12        FFQ                      3.87 (2.22--6.73)                            124 (81)               Age, gender, total energy                                                                                                                                                          8
  Jessri et al        2011   HB                  Case--control          Iran              ESCC          VB12        FFQ                      1.33 (0.60--3.03)                            143 (47)               Age, gender, energy intake, BMI, smoking status, physical activity, education level, gastroesophageal reflux disease symptoms                                                      8
  Chang et al         2015   PB                  Case--control          China             EC            VB12        Plasma                   3.07 (1.73--5.45)                            195 (93)               Age, gender, BMI, education, smoking status, alcohol drinking frequency                                                                                                            8
  Ibiebele et al      2011   PB                  Case--control          Australian        EAC           VB12        FFQ                      0.96 (0.71--1.30)                            528 (155)              Age, gender, education, BMI, alcohol intake, smoking status, energy intake, NSAID use                                                                                              8
                                                                                          ESCC          VB12        FFQ                      0.89 (0.58--1.32)                            438 (65)               Age, gender, education, BMI, alcohol intake, smoking status, energy intake, NSAID use                                                                                              8
  Xiao et al          2014   PB                  cohort                 US                ESCC          VB12        FFQ                      0.85 (0.52--1.41)                            4471303 (28)           Age, gender, race, education, marital status, health status, BMI, smoking status, alcohol, vigorous physical activity, multivitamin use, family history of cancer, energy intake   7
                                                                                          EAC           VB12        FFQ                      1.04 (0.80--1.34)                            4471303 (123)          Age, gender, race, education, marital status, health status, BMI, smoking status, alcohol, vigorous physical activity, multivitamin use, family history of cancer, energy intake   7
  Mayne et al         2001   PB                  Case--control          US                EAC           VB12        FFQ                      1.39 (1.10--1.76)                            969 (282)              Age, gender, site, race, proxy status, income, education, BMI, smoking status, alcohol, energy intake                                                                              8
                                                                                          ESCC          VB12        FFQ                      1.51 (1.15--2.00)                            893 (206)              Age, gender, site, race, proxy status, income, education, BMI, smoking status, alcohol, energy intake                                                                              8
  Fanidi et al        2014   PB                  Nested case--control   European          ESCC          VB12        Serum                    1.07 (0.51--2.23)                            274 (145)              Age, gender, country, educational attainment, smoking status, alcohol intake                                                                                                       8
                                                                                          EAC           VB12        Serum                    1.17 (0.56--2.44)                            298 (18)               Age, gender, country, educational attainment, smoking status, alcohol intake                                                                                                       8

**Abbreviations:** BMI, body mass index; EAC, esophageal adenocarcinoma; EC, esophageal carcinoma; ESCC, esophageal squamous cell carcinoma; HB, hospital-based; N/A, not available; NR, not reported; NSAID, nonsteroidal anti-inflammatory drug; PB, population-based; VB, vitamin B; FFQ, food frequency questionnaires; HHQ, health habits and history questionnaires.

###### 

Characteristics of studies on B vitamin intake

  Author                Year   Vitamin B   Exposure ascertainment   Highest vs lowest category
  --------------------- ------ ----------- ------------------------ ------------------------------------------
                                                                    
  Jessri et al          2011   VB1         FFQ                      --
  Ibiebele et al        2011   VB1         FFQ                      0.4--1.5 vs 2.1**--**5.8 (mg/d)
                               VB1         FFQ                      0.4--1.5 vs 2.1**--**5.8 (mg/d)
  Mayne et al           2001   VB1         FFQ                      --
                               VB1         FFQ                      --
  Zhang et al           1997   VB1         FFQ                      --
  Brown et al           1988   VB1         FFQ                      --
  Sharp et al           2013   VB2         FFQ                      ≤1.8 vs ≥2.8 mg (mg/d)
  Jessri et al          2011   VB2         FFQ                      --
  Ibiebele et al        2011   VB2         FFQ                      0.5--1.8 vs 2.7**--**7.1 (mg/d)
                               VB2         FFQ                      0.5--1.8 vs 2.7**--**7.1 (mg/d)
  Mayne et al           2001   VB2         FFQ                      --
                               VB2         FFQ                      --
  Bao et al             2013   VB2         Serum                    \<2,401.86 vs \>2845.42 (μg/L)
  Fanidi et al          2014   VB2         Serum                    2.5--9.4 vs 21.4**--**199 (nmol/L)
                               VB2         Serum                    2.5--9.4 vs 21.4**--**199 (nmol/L)
  Zhang et al           1997   VB2         Food records             --
  Chen et al            2009   VB2         Validated HHHQ           --
  Jessri et al          2011   VB3         FFQ                      --
  Ibiebele et al        2011   VB3         FFQ                      28--50 mg
                               VB3         FFQ                      28--50 mg
  Mayne et al           2001   VB3         FFQ                      --
                               VB3         FFQ                      --
  Zhang et al           1997   VB3         FFQ                      --
  Chen et al            2009   VB3         Validated HHHQ           --
  Jessri et al          2011   VB5         FFQ                      --
  Sharp et al           2013   VB6         FFQ                      ≤2.3 vs ≥3.2 (mg/d)
  Jessri et al          2011   VB6         FFQ                      --
  Ibiebele et al        2011   VB6         FFQ                      0.3--1.1 vs 1.5**--**3.0 (mg/d)
                               VB6         FFQ                      0.3--1.1 vs 1.5**--**3.0 (mg/d)
  Xiao et al            2014   VB6         FFQ                      --
                               VB6         FFQ                      --
  Mayne et al           2001   VB6         FFQ                      --
                               VB6         FFQ                      --
  Fanidi et al          2014   VB6         Serum                    7.2--25.6 vs 47.7**--**272 (nmol/L)
                               VB6         Serum                    7.2--25.6 vs 47.7**--**272 (nmol/L)
  Galeone et al         2006   VB6         FFQ                      --
  Zhang et al           1997   VB6         FFQ                      --
  Chen et al            2009   VB6         Validated HHHQ           --
  Ling                  2013   VB9         Serum                    \<17.04 vs \>34.19 (μg/L)
  Sharp et al           2013   VB9         FFQ                      ≤318 vs ≥421 (μg/d)
  Zhao et al            2011   VB9         FFQ                      \<230 vs \>300 (μg/d)
  Jessri et al          2011   VB9         FFQ                      --
  Chang et al           2015   VB9         Plasma                   ≤8.90 vs \>17.66 (nmol/L)
  Ibiebele et al        2011   VB9         FFQ                      42--230 vs 336--673 (μg/d)
                               VB9         FFQ                      42--230 vs 336--673 (μg/d)
  Aune et al            2011   VB9         FFQ                      --
  Xiao et al            2014   VB9         FFQ                      --
                               VB9         FFQ                      --
  Mayne et al           2001   VB9         FFQ                      --
                               VB9         FFQ                      --
  Bao et al             2013   VB9         Serum                    \<28.27 vs \>35.06 (μg/L)
  Fanidi et al          2014   VB9         Serum                    0.3--9.1 to −18.2**--**109 (nmol/L)
                               VB9         Serum                    0.3--9.1 to −18.2**--**109 (nmol/L)
  Galeone et al         2006   VB9         FFQ                      --
  Tavani et al          2012   VB9         FFQ                      \<208.77 vs \>312.47 (μg/d)
  Bollschweiler et al   2002   VB9         FFQ                      0**--**164 (μg/d)
                               VB9         FFQ                      0**--**164 (μg/d)
  Zhang et al           1997   VB9         FFQ                      --
  Qin et al             2008   VB9         FFQ                      --
  Brown et al           1988   VB9         FFQ                      --
  Chen et al            2009   VB9         HHHQ                     --
  Yang et al            2005   VB9         SQFFQ                    \<300 vs \>400 (μg/d)
  Sharp et al           2013   VB12        FFQ                      ≤6.4 vs ≥9.7 (μg/d)
  Jessri et al          2011   VB12        FFQ                      --
  Chang et al           2015   VB12        Plasma                   ≤154.23 vs \>324.06 (pmol/L)
  Ibiebele et al        2011   VB12        FFQ                      0--1.1 vs 2.1**--**7.8 (μg/d)
                               VB12        FFQ                      0--1.1 vs 2.1**--**7.8 (μg/d)
  Xiao et al            2014   VB12        FFQ                      --
                               VB12        FFQ                      --
  Mayne et al           2001   VB12        FFQ                      --
                               VB12        FFQ                      --
  Fanidi et al          2014   VB12        Serum                    75.1**--**265 vs 392**--**2,737 (pmol/L)
                               VB12        Serum                    75.1**--**265 vs 392**--**2,737 (pmol/L)

**Abbreviations:** VB, vitamin B; FFQ, food frequency questionnaires; HHHQ, health habits and history questionnaires; SQFFQ, semi-quantitative food frequency questionnaires.
